Key Drivers
- Cash Generation
- Margin Stability
- Leverage Pressure
AIAI Summary
TFX is now a balance-sheet/portfolio reset story rather than a clean compounder: it still generates cash and has liquidity, but weak earnings, thin interest coverage, and the fraud probe mean the stock only works if divestitures cut debt and management proves margin recovery and commercial traction.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Margin Stability
- •Leverage Pressure
TFX continues to generate solid operating and free cash flow with strong liquidity and stable gross margins, but persistent net losses, weak returns on capital, and interest coverage shortfalls keep the investment case under pressure.
Price Behavior
Key Price Behavior Insights:
- •Higher low
- •Range rebound
- •Overhead resistance
Over the last month, TFX has rebounded into the $133 area with improving momentum and a higher low, but it still needs to hold $129-$130 and clear $135.75 to confirm the recovery.
Sharp drop from $135.75 to $121.67 in under two weeks
Sentiment & News
Key News Insights:
- •Long-term data
- •Pivotal enrollment
- •Options activity
Teleflex is advancing its Freesolve magnesium scaffold from encouraging long-term follow-up into late-stage BIOMAG-III enrollment, while fresh options activity suggests traders are watching the stock closely.
The mix of clinical progress and elevated trading interest could support near-term sentiment for TFX, with regulatory execution now the main catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings